Form 4: Zomedica grants 1.98M SARs to Director Williams

Zomedica Corp. disclosed a grant of 1,975,033 stock appreciation rights to Director Rodney J. Williams, exercisable starting 11/16/2026 and expiring 11/16/2035.

Summary

• Director Rodney J. Williams acquired 1,975,033 Stock Appreciation Rights (SARs) on 11/17/2025 (Transaction Code: A).
• Each SAR has a conversion/exercise price of $0.10 and is tied to 1 underlying common share.
• The SARs become exercisable on 11/16/2026 and expire on 11/16/2035.
• Ownership form is Direct (D); 1,975,033 derivative securities beneficially owned following the transaction.
• No non-derivative (common stock) transactions were reported; price of derivative security listed as $0 at grant.

Sentiment

Score: 5

Explanation: Neutral administrative insider equity grant that aligns incentives but has no immediate financial impact.

Positives

• Equity award aligns director incentives with long-term shareholder value through SARs.
• Clear terms: $0.10 exercise price, exercisable 11/16/2026, expiration 11/16/2035.
• Standard long-dated incentive structure supports retention and long-term focus.

Negatives

• Potential future dilution of up to 1,975,033 common shares if SARs are settled in stock upon exercise.
• No disclosure of performance conditions or vesting schedule beyond first exercisable date.

Future Outlook

No forward-looking financial guidance or operational outlook provided; the disclosure records an insider equity award and its terms.

Industry Context

Equity-based awards such as SARs with ~10-year terms and first exercisability around one year post-grant are common across small-cap healthcare and animal health companies to align director incentives with shareholder outcomes.

Comparison to Industry Standards

• Term length (to 2035) is consistent with the typical 10-year duration seen in U.S. small-cap healthcare equity awards.
• First exercisability approximately one year after grant aligns with prevalent vesting practices for director equity in peers across animal health and broader life sciences.
• Use of SARs rather than restricted stock or traditional options is a standard alternative structure to deliver value tied to share price appreciation without upfront cash outlay.

Related Party Transactions

• Equity award of 1,975,033 SARs to Director Rodney J. Williams as part of director compensation.

Stakeholder Impact

• Shareholders: potential dilution up to 1,975,033 shares if SARs are settled in stock upon exercise.
• Directors/Employees: enhanced alignment with long-term share price performance.
• Creditors: no immediate cash impact from the grant.
• Customers/Suppliers: no direct commercial impact disclosed.

Next Steps

• SARs become exercisable on 11/16/2026, subject to their terms.
• Unexercised SARs expire on 11/16/2035.

Key Dates

Keywords

Zomedica, ZOMDF, Form 4, Stock Appreciation Right, SARs, Insider transaction, Rodney J. Williams, Equity compensation, Section 16, Director grant